Physician profile
John A Long
NPI 1861495384
$742.00
in general payments reported to CMS, 2019-2025
13 companies · $173 in 2025
The $173 reported for 2025 was less than what a typical Ophthalmic Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.35 · 2022: $13.54 · 2023: $130 · 2024: $326 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $629.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $279.64 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $76.26 | 2019 | |
| Abbvie INC. | $67.67 | 2023 | |
| Glaukos Corporation | $43.07 | 2023-2025 | Photrexa Viscous and Photrexa |
| Alcon Vision LLC | $41.14 | 2025 | Eysuvis, Tryptyr |
| Harrow Eye, LLC | $39.59 | 2025 | Vevye |
| Oyster Point Pharma, INC. | $36.65 | 2024-2025 | Tyrvaya |
| Acumed LLC | $35.69 | 2025 | Montage 5cc |
| Novartis Pharmaceuticals Corporation | $35.52 | 2022-2023 | |
| Biotissue Holdings INC. | $24.00 | 2024 | |
| Sun Pharmaceutical Industries INC. | $23.09 | 2019 | |
| Bausch & Lomb Americas INC. | $20.80 | 2024 | Xiidra |
| Rxsight INC | $18.88 | 2023 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.